Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 23, Issue 3, Pages 529-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2009.04.001
Keywords
BRAF; Melanoma; MAPK signaling; Targeted therapies; Small molecule inhibitors
Categories
Funding
- Cancer Research UK [C107/A10433]
- Institute of Cancer Research
Ask authors/readers for more resources
The RAS/RAF/MEK/ERK signaling pathway has emerged as a major player in the induction and maintenance of melanoma, particularly the protein kinase BRAF, mutated in approximately 44% of melanoma cases. The availability of new drugs affecting the components of this pathway and pathways that may cooperate with MAPK signaling, means that targeted therapies are fast becoming a real option in the clinical management of melanoma. The authors discuss what they learned from clinical trials using first- and second-generation inhibitors to this pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available